Related Experiment Video
Updated: Jun 30, 2026
07:43
Author Spotlight: A Novel Setup to Conduct Naturalistic Laboratory Experiments with Real Human Actors in Scenarios
Published on: August 4, 2023
2.9K
Structural Brain Changes in Early-Onset Alzheimer's Disease Subjects Using the LONI Pipeline Environment
Seok Woo Moon1, Ivo D Dinov2,3, Sam Hobel2
1Department of Psychiatry, Konkuk University School of Medicine, Seoul, 143-701, Korea.
Summary
Neuroimaging biomarkers reveal distinct brain structure differences in early-onset Alzheimer's Disease (EO-AD) and early-onset mild cognitive impairment (EO-MCI). These findings enhance understanding of early cognitive decline in these conditions.
Area of Science:
- Neuroimaging
- Neurology
- Biomarkers
Background:
- Early-onset Alzheimer's Disease (EO-AD) and early-onset mild cognitive impairment (EO-MCI) require further investigation.
- Utilizing neuroimaging biomarkers can expand knowledge of these early-onset neurodegenerative conditions.
Purpose of the Study:
- To investigate neuroimaging biomarkers for early-onset Alzheimer's Disease (EO-AD) and early-onset mild cognitive impairment (EO-MCI).
- To identify structural brain differences between EO-AD and EO-MCI cohorts using advanced analytical pipelines.
Main Methods:
- Analysis of 36 subjects (9 EO-AD, 27 EO-MCI) from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database.
- Application of Global Shape Analysis (GSA) and Local Shape Analysis (LSA) pipelines for neuroimaging marker extraction and statistical analysis.
- Utilizing Tensor-based Morphometry (TBM) and multivariate regression to assess structural brain differences.
Main Results:
- Global Shape Analysis identified 15 significant neuroimaging markers differentiating the cohorts.
- Local Shape Analysis and TBM revealed significant regional shape differences influenced by diagnosis and other covariates, with some effects surviving FDR correction.
Conclusions:
- The identified neuroimaging markers and structural differences may help explain variations between EO-AD and EO-MCI.
- These findings contribute to understanding the characteristics of early cognitive impairment in these conditions.
More Related Videos
07:07Tumor Hypoxia Assessment: In Vivo 3D Oxygen Imaging Through Electron Paramagnetic Resonance
Published on: February 14, 2025
4.1K
12:06Transmission Electron Microscopy as the Visualization Technique for Analysis of Circadian Synaptic Plasticity in the Mouse Barrel Cortex
Published on: August 19, 2025
1.2K
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:14Brain Imaging
Brain imaging technologies provide critical insights into both the structure and function of the human brain, enabling medical professionals and researchers to diagnose, study, and treat neurological disorders or psychiatric disorders more effectively.
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic Stimulation (TMS).
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic Stimulation (TMS).
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...